- $146.64m
- $175.11m
- $88.50m
Annual cashflow statement for Biodesix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43.2 | -65.4 | -52.1 | -42.9 | -35.3 |
| Depreciation | |||||
| Non-Cash Items | 7.17 | 20.3 | 12 | -13.1 | 5.94 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.59 | -3.44 | 14 | 1.59 | 0.383 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -28.2 | -45 | -22.9 | -48.6 | -23.3 |
| Capital Expenditures | -2.55 | -3.53 | -23.1 | -3.44 | -0.403 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale of Business | |||||
| Cash from Investing Activities | -2.55 | -3.53 | -23.1 | -3.44 | -0.403 |
| Financing Cash Flow Items | -0.5 | -17.4 | -9.04 | -3.55 | -0.882 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.26 | 58.9 | 29.1 | 52 | 16.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -29.5 | 10.4 | -16.8 | -0.039 | -7.26 |